These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 24840285)

  • 41. Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies.
    Chen J; Chi S; Li F; Yang J; Cho WC; Liu X
    Expert Opin Biol Ther; 2017 Mar; 17(3):265-283. PubMed ID: 28117616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biologic Therapies for Autoimmune and Connective Tissue Diseases.
    Wolfe RM; Ang DC
    Immunol Allergy Clin North Am; 2017 May; 37(2):283-299. PubMed ID: 28366477
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
    Strand V; Ahadieh S; French J; Geier J; Krishnaswami S; Menon S; Checchio T; Tensfeldt TG; Hoffman E; Riese R; Boy M; Gómez-Reino JJ
    Arthritis Res Ther; 2015 Dec; 17():362. PubMed ID: 26669566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [THE EFFECT OF BIOLOGIC THERAPY ON THE LIPID PROFILE OF RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA) AND ANKYLOSING SPONDYLITIS (AS) PATIENTS].
    Hassan S; Feld J; Cohen S; Zisman D
    Harefuah; 2017 Jul; 156(7):446-450. PubMed ID: 28786273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients.
    Mekinian A; Dervin G; Lapidus N; Kahn JE; Terriou L; Liozon E; Grignano E; Piette JC; Rauzy OB; Grobost V; Godmer P; Gillard J; Rossignol J; Launay D; Aouba A; Cardon T; Bouillet L; Broner J; Vinit J; Ades L; Carrat F; Salvado C; Toussirot E; Versini M; Costedoat-Chalumeau N; Fraison JB; Guilpain P; Fenaux P; Fain O;
    Autoimmun Rev; 2017 Sep; 16(9):903-910. PubMed ID: 28705782
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis.
    Maneiro JR; Souto A; Gomez-Reino JJ
    Semin Arthritis Rheum; 2017 Oct; 47(2):149-156. PubMed ID: 28284845
    [TBL] [Abstract][Full Text] [Related]  

  • 48. End-stage renal disease in patients with rheumatoid arthritis.
    Paudyal S; Yang FM; Rice C; Chen CC; Skelton M; Bethel M; Brown S; Nahman NS; Carbone L
    Semin Arthritis Rheum; 2017 Feb; 46(4):418-422. PubMed ID: 27591827
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.
    Jani M; Dixon WG; Chinoy H
    Rheumatology (Oxford); 2018 Nov; 57(11):1896-1907. PubMed ID: 29325166
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
    Collamer AN; Battafarano DF
    Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
    Ramiro S; Gaujoux-Viala C; Nam JL; Smolen JS; Buch M; Gossec L; van der Heijde D; Winthrop K; Landewé R
    Ann Rheum Dis; 2014 Mar; 73(3):529-35. PubMed ID: 24401994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.
    Iannone F; Ferraccioli G; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Gorla R; Bazzani C; Govoni M; Farina I; Gremese E; Carletto A; Giollo A; Galeazzi M; Foti R; Bianchino L; La Grasta L; Lapadula G
    Clin Rheumatol; 2018 Feb; 37(2):315-321. PubMed ID: 28980085
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
    García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
    Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Machado-Alba JE; Ruiz AF; Machado-Duque ME
    Rev Panam Salud Publica; 2014 Dec; 36(6):396-401. PubMed ID: 25711751
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
    Mariette X; Gottenberg JE; Ravaud P; Combe B
    Rheumatology (Oxford); 2011 Jan; 50(1):222-9. PubMed ID: 21148156
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions.
    Desai RJ; Huybrechts KF; Bateman BT; Hernandez-Diaz S; Mogun H; Gopalakrishnan C; Patorno E; Kim SC
    Arthritis Rheumatol; 2016 May; 68(5):1183-9. PubMed ID: 26606742
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using "National Database of Health Insurance Claims and Specific Health Checkups of Japan".
    Kamata Y; Minota S
    Rheumatol Int; 2018 Apr; 38(4):663-668. PubMed ID: 29204683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.